# Tango Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Tango Therapeutics, Inc.). ## Overview Tango Therapeutics, Inc. is a U.S.-based precision oncology company focused on discovering and developing targeted cancer therapies for genetically defined patient populations. Its pipeline centers on small-molecule drug candidates designed to selectively attack cancer cells with specific genetic alterations while sparing normal cells. ## Products & services • MTAP-deleted selective PRMT5 inhibitor vopimetostat (TNG462) • Brain-penetrant PRMT5 inhibitor TNG456 for CNS cancers • CoREST inhibitor program TNG260 • Target discovery and translational oncology platform • Clinical-stage oncology drug development - **Clinical-stage oncology programs** (80%) — Drug candidates in human clinical development for genetically defined cancers. - **Collaboration revenue** (20%) — Revenue recognized from partnered research and licensing arrangements. - **Target discovery platform** (0%) — Internal discovery capabilities used to identify disease-relevant oncology targets. - MTAP-deleted selective PRMT5 inhibitor vopimetostat (TNG462) - Brain-penetrant PRMT5 inhibitor TNG456 for CNS cancers - CoREST inhibitor program TNG260 - Target discovery and translational oncology platform - Clinical-stage oncology drug development ## Customers Tango Therapeutics does not sell commercial products today; its economic counterparties are pharmaceutical collaborators, research partners, and future oncology patients through regulated drug development. In the current model, revenue is primarily tied to collaboration agreements, while the eventual commercial customer base would be hospitals, oncologists, and payors if product candidates are approved. - **Pharmaceutical collaboration partners** (primary) — Buy access to discovery, research, and licensing rights in oncology programs. - **Future oncology treatment providers** (secondary) — Hospitals, cancer centers, and oncologists that would use approved therapies. - **Payers and reimbursement decision-makers** (secondary) — Assess clinical value and coverage for any approved cancer medicines. - **Research and translational science partners** (emerging) — Support target validation, biomarker work, and early-stage development. - Pharmaceutical collaborators funding or sharing oncology research - Future hospitals and cancer centers that would prescribe approved drugs - Oncologists treating genetically defined solid tumors and CNS cancers - Payers and health systems that would evaluate reimbursement and access - Research partners supporting target discovery and translational studies ## Geography The company is headquartered in the United States and conducts its core research and development activities from Boston, Massachusetts. Its operational footprint also depends on third-party manufacturing and clinical supply chains, including a supplier located in China, which creates geographic exposure in both development execution and supply continuity. - Headquartered in the United States - Boston, Massachusetts is a key office and laboratory location - Clinical and regulatory activity is centered in the U.S. and other major markets - Third-party API and drug-product supply includes China exposure - Future commercialization would likely expand into U.S. and ex-U.S. markets ## Strategy Tango Therapeutics is focused on advancing genetically targeted oncology programs through clinical proof-of-concept and biomarker-driven development. Its strategy relies on selecting cancer vulnerabilities such as MTAP deletion and building differentiated small molecules that can be paired with combination regimens or used in CNS settings. - **Advance vopimetostat and TNG456 in clinical development** (short-term) — Clinical validation is the main path to value creation for a pre-commercial oncology company. - **Differentiate through genetically defined patient selection** (medium-term) — Targeting MTAP-deleted tumors can improve selectivity and clinical relevance. - **Expand combination and CNS opportunities** (medium-term) — Combination regimens and brain-penetrant assets broaden the addressable oncology market. - **Preserve access to external funding and partnerships** (short-term) — The company depends on collaboration revenue and capital markets to finance development. - Advance MTAP-deleted selective PRMT5 inhibitors through clinical trials - Develop brain-penetrant oncology assets for CNS tumors such as glioblastoma - Use biomarker-defined patient selection to improve clinical differentiation - Maintain discovery capability while prioritizing the most promising programs - Use collaborations and licensing to fund development and extend runway ## Risks The company faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory approval risk, and the need for substantial external funding before any product sales. It also has meaningful supply-chain concentration, including single-source or limited-source API and drug-product manufacturing, and its oncology programs face intense competition from other PRMT5 and precision oncology developers. - **Clinical development failure** [high] — Pipeline value depends on demonstrating safety and efficacy in human trials. - **Manufacturing and supply concentration** [high] — API and drug product rely on a small number of third-party suppliers. - **China-related supply chain exposure** [medium] — One CDMO is located in China, creating geopolitical and logistics risk. - **Capital dependence** [high] — The company must fund long-duration R&D before product revenue exists. - **Competitive pressure in oncology** [medium] — Other companies are developing PRMT5 and related precision oncology programs. - **Pricing and reimbursement risk** [medium] — Future approved therapies may face coverage limits and pricing pressure. - Clinical failure risk across PRMT5 and CoREST programs - No approved products, so value depends on future regulatory success - Single-source or limited-source manufacturing can disrupt trials - Competition is intense in precision oncology and PRMT5 inhibition - Reimbursement and pricing pressure could limit future commercialization ## Accounting The most important accounting issue is revenue recognition for collaboration agreements, where upfront payments, license fees, extension fees, and milestones may be recognized over time or at specific points depending on contract terms. Investors should also watch estimates around deferred revenue, contingent milestone obligations, lease liabilities for lab and office space, and the valuation of any future collaboration-related assets or obligations. - **Revenue recognition for collaborations** — Affects timing and volatility of reported revenue - **Deferred revenue** — Can materially shift revenue between quarters and years - **Contingent milestone and royalty obligations** — Affects future expense recognition and cash outflows - **Lease accounting** — Affects balance sheet leverage and operating expense presentation - **Clinical trial and manufacturing accruals** — Can affect R&D expense timing and comparability - Collaboration revenue timing depends on performance obligations and contract terms - Upfront and extension payments can create deferred revenue balances - Milestones and royalties are contingent and may be difficult to estimate - Operating lease accounting affects lab and office occupancy costs - Clinical supply and vendor commitments can create judgment-heavy accruals --- *Last updated: 2026-04-29T05:02:57.910450+00:00*